Poland has by far the highest shares of generic drugs market penetration in the OECD (Figure 15), representing 75% in volume terms and 58% in value, which contributes to the comparatively low price of drugs (in Purchasing Power Parity terms) (OECD, 2008a). They then provide the cheaper drug on patients’ request. However, in practice, these obligations are rarely met.